Although the detailed regulation mechanism of EP4–YAP signaling was not fully understood, our results provide a clear rationale for exploring EP4 blockade to target the aberrant activation of YAP in pancreatic cancer and other human diseases in which YAP has a pathological role. This evidence concerns the gene YAP1 and familial pancreatic carcinoma.